Literature DB >> 27061015

Do patients with tuberous sclerosis complex have an increased risk for malignancies?

Angela Peron1, Aglaia Vignoli1, Francesca La Briola1, Angela Volpi2, Emanuele Montanari3, Emanuela Morenghi4, Filippo Ghelma5, Gaetano Bulfamante6, Graziella Cefalo7, Maria Paola Canevini1.   

Abstract

Tuberous Sclerosis Complex (TSC) is generally characterized by the presence of benign tumors, but some patients with malignancies have been reported in the literature. We examined a large Italian TSC population (240 individuals followed from 2001 to 2015, aged 3 months-74 years), assessing the frequency of malignancies to determine whether there is an increased risk for cancer in this disorder, and looking for possible features associated with the development of neoplasia. Fifteen patients had malignancies (6.25%); median age at diagnosis was 37.5 years (range of 1.6-58). Five of seven renal tumors were renal cell carcinomas. Eight patients had a non-renal malignancy (3.3%), but we did not find a more prevalent type of cancer. No patient developed more than one malignancy. The prevalence of all malignant tumors was compatible with the prevalence in the general population (5.6%, 95%CI 2.99-9.31%, vs. 4.4% in Italy). Median age at cancer diagnosis was lower (37.5 years, 95%CI 28.6-44.7, vs. 66.0 years). Two patients (13.3%) died of their cancer, while outcome was favorable in the remaining individuals. Malignant tumors were more frequently diagnosed in patients with mutations in TSC1 when compared to TSC2 and patients with no mutation identified (P = 0.032). Our study demonstrated that TSC patients do not seem to have an increased risk for malignancies besides renal cell carcinoma. However, when cancer develops, age at diagnosis is lower than in the general population, and malignant tumors are more frequently diagnosed in patients with mutations in TSC1. Further studies are needed to confirm these data. ©2016 Wiley Periodicals, Inc.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  TSC; TSC1; TSC2; cancer; malignancy; neoplasia; tuberous sclerosis complex; tumor

Mesh:

Year:  2016        PMID: 27061015     DOI: 10.1002/ajmg.a.37644

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.

Authors:  Doreen N Palsgrove; Yunjie Li; Christine A Pratilas; Ming-Tseh Lin; Aparna Pallavajjalla; Christopher Gocke; Angelo M De Marzo; Andres Matoso; George J Netto; Jonathan I Epstein; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2018-09       Impact factor: 6.394

Review 2.  Diagnostic management of occult nodal lymphangioleiomyomatosis detected during pelvic cancer staging. Localized finding or systemic disease?

Authors:  Andrea Remo; Caterina Zanella; Pietro Parcesepe; Filippo Greco; Massimo Pancione; Mara Maria Zapparoli; Erminia Manfrin; Claudio Micheletto
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

3.  Cortical blindness as severe neuro-ophthalmological manifestation of tuberous sclerosis complex.

Authors:  Alvaro I Ortiz Z; Pedro Luis Cárdenas; Luis C Escaf; Marcela Peralta
Journal:  GMS Ophthalmol Cases       Date:  2017-04-19

4.  A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report.

Authors:  Stéphane Auvin; John J Bissler; Vincent Cottin; Ayataka Fujimoto; Günther F L Hofbauer; Anna C Jansen; Sergiusz Jóźwiak; Larissa Kerecuk; J Christopher Kingswood; Romina Moavero; Roser Torra; Vicente Villanueva
Journal:  Orphanet J Rare Dis       Date:  2019-04-30       Impact factor: 4.123

Review 5.  A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC).

Authors:  Johann Philipp Zöllner; David Neal Franz; Christoph Hertzberg; Rima Nabbout; Felix Rosenow; Matthias Sauter; Susanne Schubert-Bast; Adelheid Wiemer-Kruel; Adam Strzelczyk
Journal:  Orphanet J Rare Dis       Date:  2020-01-21       Impact factor: 4.123

6.  Pathogenic ATM and BAP1 germline mutations in a case of early-onset, familial sarcomatoid renal cancer.

Authors:  Hannah N Bell; Chandan Kumar-Sinha; Rahul Mannan; Dana Zakalik; Yuping Zhang; Rohit Mehra; Deepa Jagtap; Saravana M Dhanasekaran; Ulka Vaishampayan
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-04-28

Review 7.  Healthcare transition from childhood to adulthood in Tuberous Sclerosis Complex.

Authors:  Angela Peron; Maria Paola Canevini; Filippo Ghelma; Fabiano Di Marco; Aglaia Vignoli
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-09-25       Impact factor: 3.908

8.  Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA).

Authors:  Matthias Sauter; Elena Belousova; Mirjana P Benedik; Tom Carter; Vincent Cottin; Paolo Curatolo; Maria Dahlin; Lisa D'Amato; Guillaume B d'Augères; Petrus J de Vries; José C Ferreira; Martha Feucht; Carla Fladrowski; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Ruben Marques; Rima Nabbout; Finbar O'Callaghan; Jiong Qin; Valentin Sander; Seema Shah; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; Anna Jansen; J Chris Kingswood
Journal:  Orphanet J Rare Dis       Date:  2021-07-06       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.